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Background: While functional foods oﬀer promise for public health and innovation in the food industry, the
eﬃciency of such foods should be assured to protect consumers from misleading claims. Globally, many
countries regulate the communication of the health eﬀects of such foods to ﬁnal consumers.
Scope and approach: In the European Union (EU), the use of health claims was harmonized in 2006. All claims
need to be scientiﬁcally assessed by the European Food Safety Authority (EFSA) and pre-approved.
Implementing the regulation has involved a steep learning curve for stakeholders, resulting in many health
claims being rejected. The EU-funded REDICLAIM project used existing guidance documents, analyses of
Scientiﬁc Opinions on new health claim applications, and a series of interviews with experts involved in such
applications to identify key points in the process of authorizing new health claims.
Key ﬁndings and conclusions: Recommendations for the successful substantiation of new health claims in the EU
were prepared. The substantiation of health claims is primarily based on human eﬃcacy studies, and greater
resources are required to authorize more innovative claims. The reported recommendations should be seen as a
starting point for researchers in the area of nutrition and food technology, and for those dealing with functional
foods, including the food industry.
1. Introduction
Nutrition is recognized as an important modiﬁable factor inﬂuen-
cing human health. While overconsumption of energy-dense foods re-
sults in high energy intakes and growing incidence of obesity and a
series of non-communicable diseases, speciﬁc populations are still at
risk of nutrient deﬁciencies. Foods are a source of nutrients for the
human body, but can also support body functions beyond adequate
nutritional eﬀects – providing health beneﬁts. Discussions regarding
functional food as a regulatory concept originated in Japan in late
1980s (Kwak & Jukes, 2001; Weststrate, van Poppel, & Verschuren,
2007). The development of functional foods was later particularly af-
fected by regulations related to the use of health claims on foods
(Ashwell, 2002; Weststrate et al., 2007). In the USA, evidence-based
health or disease prevention claims have been allowed since 1990,
when the Nutrition Labelling and Education Act was adopted
(Arvanitoyannis & Houwelingen-Koukaliaroglou, 2005). In the Eur-
opean Union (EU), harmonization was achieved in 2006 with Regula-
tion (EC) No 1924/2006 on nutrition and health claims made on foods
(NHCR) (EC, 2006), which requires health claims to be authorized
before market entry (Verhagen & van Loveren, 2016). There is evidence
of substantive use of health claims in EU countries, particularly in
certain food categories (Hieke et al., 2016; Kaur et al., 2016; Kaur et al.,
2015; Lalor, Kennedy, Flynn, & Wall, 2010; Lopéz-Galán & De-
Magistris, 2017; Pravst & Kušar, 2015; Storcksdieck genannt Bonsmann
et al., 2010). In a 2013 study, about 7–14% of pre-packed foods in
selected EU countries were found to carry health claims (Hieke et al.,
2016).
While functional foods with health claims provide opportunity for
fostering innovation in the food sector and improving public health,
there are also potential risks associated with their use, for example the
lack of beneﬁcial health eﬀects or even health concerns which may
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arise from the regular consumption of these foods. Therefore many
countries carefully regulate the use of health claims (de Boer & Bast,
2015).
The rationale behind the requirement for pre-approval of all speciﬁc
health claims is ensuring fair competition and eﬀective functioning of
the internal EU market, as well as protection of consumers from mis-
leading claims (EC, 2006). The latter is particularly important because
health beneﬁts are credence attributes, that is qualities that cannot be
observed by a consumer. After a scientiﬁc assessment by the European
Food Safety Authority (EFSA), the NHCR requires all health claims to be
authorized by the European Commission (EC) through the comitology
procedure (EC, 2017c). The Commission must act in line with the
principles of good administration, and this imposes a duty of care on the
Commission to act in good faith (“Demo-Studio Schmidt v
Commission,” 1983), to give due consideration to all the arguments
presented (“Nolle v HZA Bremen-Freihafen,” 1991), and to the task in
hand (“Commission v Estonia,” 2012). In particular, Recital 16 of the
NHCR requires the Commission to ensure that the claim can be well
understood by consumers.
A key aspect of any health claim application is the provision of
evidence regarding the cause-eﬀect relationship between consumption
of the food (constituent) and the claimed health outcome (Martínez &
Siani, 2017; Navas-Carretero & Martinez, 2015). Implementing the
NHCR has involved a steep learning curve for diﬀerent stakeholders,
including policy makers and authorities in the EU member states, the
EFSA, and the food industry (Martin, 2015; Vero & Gasbarrini, 2012),
with several suggestions having been made to improve it (Cappuccio &
Pravst, 2011; de Boer, Urlings, & Bast, 2016; Kaur et al., 2016; Pravst,
2011). In many cases, health claim applications were evaluated with a
negative outcome by the EFSA – often because they were not supported
by suﬃcient scientiﬁc evidence (Verhagen & van Loveren, 2016). While
an important objective of the NHCR was to foster innovation in the food
sector, some evidence suggests that the opposite might be the case
(Bröring, Khedkar, & Ciliberti, 2017; Khedkar, Ciliberti, & Bröring,
2016).
The challenges associated with the use and substantiation of health
claims have been recognized by the European Commission (EC), re-
sulting in the funding of speciﬁc projects in the EC's Seventh
Framework Programme on topics including the role of health claims in
consumer behaviour [CLYMBOL project (Hieke et al., 2015)] and food
constituents that show potential [FIBEBIOTICS project (Mes, 2013),
BACCHUS project (Buttriss, 2015)]. The REDICLAIM project was
funded, with the aim to assess the NHCR, where a particular emphasis
was on “reduction of disease risk” (RDR) claims (so called Art 14.1.a
claims), and also new function claims (so called Art 13.5 claims). The
project's focuses are: (1) understanding the main issues and hurdles
concerning the substantiation and use of health claims on foodstuﬀs,
and the level of awareness about legal obligations regarding the use of
claims among the relevant stakeholders; and (2) to produce a three-fold
study of the NHCR's impact on the claim substantiation process, health
research and/or innovation in the food chain, and nutrition economic
models – to determine the health impact (Raats et al., 2015). Another
key project objective was to support the food business in the enhanced
development of innovative and competitive products, and their better
compliance with the regulation.
2. Methodology and approaches
One of the REDICLAIM's work streams ascertained the interaction
between legislation and the claim substantiation process, and on pre-
pared key recommendations for the successful substantiation of new
health claims in the EU – covering new function claims, as well as and
RDR claims.
The health claims legislation in selected developed countries/re-
gions (EU, USA, Canada and Australia/New Zealand) was compared,
focusing on the advantages and disadvantages of diﬀerent solutions
from a research and development perspective (Raats et al., 2016). In all
selected jurisdictions, RDR claims must be pre-approved before being
used in the market. Applicants are usually food companies or producers
of food ingredients and the application procedures are well deﬁned. The
strength of scientiﬁc evidence needed to substantiate such health claims
is typically described as “generally accepted scientiﬁc evidence of
beneﬁcial physiological eﬀect in humans” (EU), “signiﬁcant scientiﬁc
agreement” (USA and Canada), and an “established food-health re-
lationship based on the totality and weight of evidence” (Australia and
New Zealand) (Raats et al., 2016).
Health claim applications receiving an unfavourable evaluation
from EFSA are either a result of poor quality available scientiﬁc data, or
poor presentation of such data (i.e. the quality of the application)
(Martínez & Siani, 2017; Pravst, 2010). In order to understand this in
more detail, existing EFSA Opinions on new health claim applications
were analysed, and interviews were conducted with experts experi-
enced in preparing health claim dossiers, mostly from the food industry
and research consultancy service providers specialized in the health
claim authorization process. Analysis of the EFSA's Opinions focused on
all, favorable and unfavorable, applications for RDR claims after the
NHCR was introduced in 2007. Critical issues were identiﬁed and
coded. Interviews were conducted with successful and unsuccessful
RDR claim and new function health claim applicants. In practice, these
claims can result in the authorization of company-speciﬁc, proprietary
health claims, and may therefore represent a driving force for innova-
tion in the food industry. Interviewees found the health claim appli-
cation process to be either easy or challenging, depending on the no-
velty of the claimed health beneﬁt and/or underlying science. The
process was perceived as straightforward for food constituents for
which existing knowledge can be exploited (e.g. for various well in-
vestigated types of dietary ﬁbre in relationship to cholesterol lowering),
while the process was regarded as much more challenging for health
claims based on emerging scientiﬁc ﬁndings (i.e. less investigated types
of ﬁbre, plant extracts and their speciﬁc constituents, probiotics).
Based on the results of the above mentioned literature review of
EFSA Opinions and interviews, key recommendations for the successful
substantiation of new health claims in the EU (Fig. 1) were identiﬁed
and a draft document containing the recommendations was prepared
Analyses of
EFSA opinions
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Fig. 1. Schematic approach to identifying key recommendations for
the successful substantiation of new health claims in the European
Union.
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for consultation with experts from the food industry, research con-
sultancy providers specialized in the health claim authorization pro-
cess, academics, the EC and the EFSA. Experts were invited to provide
comments and suggestions on the draft recommendations, which were
next discussed at a workshop in Brussels in February 2017. All com-
ments were discussed at a post-workshop consortium meeting, resulting
in a revised version of the recommendations, which was sent for a ﬁnal
review to the consortium members and selected key external experts;
resulting in a ﬁnal list of key recommendations, as set out below.
3. Recommendations for the successful substantiation of new
health claims in the European Union
The decision to start the application process for the authorization of
a new health claim should be taken with care. While a new health claim
can beneﬁt food business operations, the application process requires
time and eﬀort. Companies can apply for new health claims for a
variety of reasons, not just the communication of health beneﬁts to the
consumer. Reasons include the opening of new business-to-business
channels, increasing a company's reputation, and in some cases also
inﬂuencing decisions in countries outside the EU. A key question at the
outset of the application process is whether the particularly claim in
fact falls within the scope of the NHCR. In the EU, medicinal claims are
not allowed on foodstuﬀs (EC, 2011). Moreover, some claims that are
only considered to be indirectly related to health are not considered to
fall within the scope of the regulation. An example of this are claims
referring to the improved bioavailability of food constituents to which
the general food labelling regulation applies (EC, 2011), requiring that
information provided on foods is correct and not misleading for con-
sumers.
The REDICLAIM project identiﬁed the following recommendations
to support the preparation of applications for new function claims and
RDR health claims in the EU:
• Consider the EFSA's extensive guidance documents on the
submission and substantiation of health claims. These docu-
ments are considerably revised from time to time as a result of the
experience gained in previous evaluations, and therefore the EFSA's
webpage1 is an excellent starting point for anyone interested in new
health claims.
A second revision of the Scientiﬁc and technical guidance for the pre-
paration and presentation of a health claim application was published
in 2017 (EFSA, 2017c), with more details of the requirements as-
sociated with presenting unpublished data. While this guidance
provides all the details of how a health claim application should be
compiled, including the requisite forms, the general scientiﬁc prin-
ciples used by the EFSA in the evaluation of health claims are pro-
vided in the General scientiﬁc guidance for stakeholders on health claim
applications (EFSA, 2016a). In addition, a series of documents pro-
vides speciﬁc guidance on the scientiﬁc requirements for health
claims related to speciﬁc health relationships (Table 1). These
documents are also occasionally revised. The guidance for health
claims related to the immune system, the gastrointestinal tract and
defence against pathogenic microorganisms was revised in 2016
(EFSA, 2016b), while the guidance targeting antioxidants, oxidative
damage and cardiovascular health is currently undergoing revision
(EFSA, 2017b).
• Consider the EFSA's previous Opinions, particularly those
published since the last revision of speciﬁc guidance con-
cerning the health outcome in question. All health claim appli-
cations are publicly listed in the EFSA's Register of Questions (EFSA,
2017a) and the Opinions are published in the open-access EFSA
Journal. These Opinions provide important comments on study
designs and (in) appropriate biomarkers for certain health out-
comes. Opinions related to the health outcome in question can be
particularly valuable, even if they refer to other food constituents. It
is also important to note both Opinions with favorable and un-
favorable outcomes.
• Consider the novelty of the food (constituent) and the science
providing the evidence. In the case of novelty, the claim applica-
tion process will require considerable resources and a careful con-
sideration of the strength of the evidence linking consumption of the
food constituent and the health outcome. When the application is
based on a new health eﬀect, no previous evaluations are available
for use as a reference point.
• Consider the results of key EU-funded research projects dealing
with health claims. All funded projects are listed at the CORDIS
portal (EC, 2017b) and have resulted in useful guidance documents,
for example the Guidance for the design and implementation of
human dietary intervention studies for health claim submissions
(Lucey, Heneghan, & Kiely, 2016) produced within the BACCHUS
project (the toolkit is available at the EuroFIR website: www.euroﬁr.
org).
• Evaluation time can be cut considerably if the health claim
application (dossier) contains details of all pertinent data. For
unpublished data, full study reports are needed; the submission of
abstracts or incomplete data will result in a delay – either before the
evaluation process, or by way of a ‘stop-the-clock’ procedure during
the evaluation. In the case of new function claims, applicants only
have 15 days to provide clariﬁcations or additional data, while in
the case of RDR claims the clock-stop time can be negotiated with
the EFSA depending on the type and amount of additional in-
formation requested (EFSA, 2014).
• Data protection is possible when the scientiﬁc substantiation is
primarily based on companies' own data. When the substantia-
tion of a health claim is based on (unpublished) proprietary data and
the health claim cannot be substantiated without such data, the
applicant can request ﬁve years of data protection. Such a request
needs to be included in the health claim application. If data pro-
tection is not granted, all food business operators will be allowed to
use the health claim in the EU immediately after the health claim
has been authorized (on foods complying with the deﬁned condi-
tions of use).
• In the process of scientiﬁcally evaluating a health claim, the
safety of a food (constituent) is not systematically assessed. If a
food (constituent) is not authorized for sale in the EU market, its
safety needs to be cleared in a separate process for authorizing a
novel food (ingredient) (EC, 2017a). The submission of a new health
claim application for a non-authorized (novel) food (constituent)
could result in a scenario where the oﬃcially authorized heath claim
cannot be used in practice because the product cannot be put on the
market. In the EU, the regulation of novel foods has been harmo-
nised since 1997 (EU, 1997), however the new regulation (EU)
2015/2283 on novel foods will come into force in January 2018
(EC, 2015). When data protection is requested (Art. 28), the new
regulation provides the possibility for a parallel authorisation pro-
cedures for novel foods (ingredients) and health claims (EC, 2015).
• Assure that the food (constituent) can be suﬃciently char-
acterized. A precondition of any health claim is that the evidence
should be provided for a well-characterized food (constituent), and
that food authorities will be able to control use of the authorized
claim in practice (where applicable, appropriate laboratory methods
should be provided). When the proposed health claim refers to a
combination of food constituents, all active constituents should be
suﬃciently characterized. The EFSA has published recommenda-
tions for characterizing plant products and microorganisms in gui-
dance documents (EFSA, 2016a).
• A health claim's wording must reﬂect the scientiﬁc evidence
and should be (where applicable)comparable with already1 https://www.efsa.europa.eu/en/applications/nutrition/regulationsandguidance.
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authorized claims. If the proposed wording of a health claim is not
comparable with a similar authorized claim (e.g. where a similar
claim has already been authorized for another food constituent) it is
quite likely the wording will be changed during the authorization
process. All authorized health claims are listed in the EU Register of
nutrition and health claims made on foods (EC, 2017d). Unless a
propriety claim is being sought, the use of brand names should be
avoided. As seen from the EU Register, the wording of authorized
health claims mostly refers to the generic name of the food (con-
stituent) for which the evidence was provided in the authorization
process.
• The claimed eﬀect should be clearly deﬁned and relevant for
human health. A number of eﬀects have to date not considered to
have been relevant (e.g., an increase in the number of biﬁdobacteria
in the gut, a reduction of the waist circumference) (Pravst, 2010).
• For all claims other than those based on the essentiality of
nutrients, the substantiation of a health claim should primarily
be based on good quality human eﬃcacy studies. Randomized
controlled trials (RCT) are considered as a gold standard. Non-
blinded RCTs are acceptable in cases where blinding is not possible.
In weighing up the evidence, all aspects of the design and quality of
the studies are considered (including the risk of bias). Tools for
assessing study quality are available (EFSA, 2015).
• The proposed conditions of use should reﬂect the conditions in
which the studies used for substantiating the claim were con-
ducted. If not otherwise speciﬁed, health claims should be directed
to the general population. The population used for claim sub-
stantiation should reﬂect the target population. Alternatively, the
speciﬁc study group in which the evidence was obtained should
enable the results to be extrapolated to the proposed target popu-
lation. Particular attention is needed when studies are not con-
ducted with a healthy population. It is also important to ensure that
the consumer can reasonably consume enough of the food (con-
stituent) as part of a balanced diet to obtain the claimed eﬀect.
• The application should provide the totality of the available
scientiﬁc data. Applications must also include unpublished results
and studies that show no or the opposite eﬀects. Results of un-
published studies should be delivered with full study reports.
Reporting should be in line with the International Conference on
Harmonization (ICH) guideline E3 on the structure and content of
clinical study reports (ICH, 1995), adapted for the purpose of health
claim substantiation. Appropriate standards should also be used in
proprietary studies. Consider Good Clinical Practice and take care of
all safety and ethical aspects, including appropriate informed con-
sents. Studies should be registered in an on-line clinical trials reg-
istry using one of the registers included in the WHO International
Clinical Trials Registry Platform (ICTRP) (WHO, 2017) before the
ﬁrst subject is recruited.
• Successful scientiﬁc substantiation of a health claim does not
ensure that it will be authorized. Based on the Scientiﬁc Opinion,
the EC prepares a draft decision for submission to the Standing
Committee on Plants, Animals, Food and Feed (PAFF). After this
Committee votes in its favor, the European Parliament and the
Council have the right of scrutiny over the proposed decision. If
there is no objection, the EC adopts the decision. There are examples
of scientiﬁcally substantiated health claims which have not been
authorized due to public health concerns (i.e. safety issues; classi-
ﬁcation of the food constituent as a medicine in most member states;
claims not in line with current dietary recommendations). A typical
example of such a scenario is a health claim related to hydro-
xyanthracene derivatives and improvement of bowel function
(EFSA, 2013), which was not authorized due to safety concerns
expressed by the EU member states.
In conclusion, the key recommendations outlined above were
identiﬁed to support applicants in preparing successful applications for
new function claims and RDR health claims in the European Union. The
outcome of this process provides key references and highlights the is-
sues to be addressed in all phases of the authorization of new claims –
from deciding whether to apply for a new heath claim and the for-
mulation of its wording, establishing and collecting the supporting
evidence through to the post-evaluation process, and the ﬁnal speciﬁ-
cation of the health claim for formal incorporation into the Annex of the
regulation. The recommendations should be seen as a starting point for
researchers in the area of nutrition and food technology, and for those
dealing with functional foods, including the food industry.
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